Quantbot Technologies LP Sells 121,439 Shares of GSK plc (NYSE:GSK)

Quantbot Technologies LP cut its position in GSK plc (NYSE:GSK - Free Report) by 57.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 89,371 shares of the pharmaceutical company's stock after selling 121,439 shares during the period. Quantbot Technologies LP's holdings in GSK were worth $3,023,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Primecap Management Co. CA grew its position in GSK by 70.1% in the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock valued at $854,349,000 after purchasing an additional 10,407,905 shares in the last quarter. FMR LLC increased its stake in shares of GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Mondrian Investment Partners LTD raised its stake in GSK by 17.6% in the 4th quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company's stock worth $205,920,000 after purchasing an additional 874,004 shares in the last quarter. Fisher Asset Management LLC lifted its position in shares of GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company's stock valued at $759,425,000 after acquiring an additional 870,449 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC lifted its position in shares of GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company's stock worth $144,803,000 after buying an additional 833,080 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

Remove Ads

GSK Trading Up 0.0 %

NYSE GSK traded up $0.01 on Tuesday, reaching $38.58. The company had a trading volume of 4,247,249 shares, compared to its average volume of 4,344,529. The firm has a market cap of $79.84 billion, a price-to-earnings ratio of 24.26, a P/E/G ratio of 1.12 and a beta of 0.58. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.93. The business has a 50 day moving average of $36.77 and a two-hundred day moving average of $36.84. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Analysts forecast that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a yield of 4.08%. The ex-dividend date of this dividend is Friday, February 21st. GSK's payout ratio is 98.74%.

Analyst Upgrades and Downgrades

GSK has been the subject of several research analyst reports. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, February 7th. Morgan Stanley assumed coverage on GSK in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.